CN110496231B - 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用 - Google Patents

一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用 Download PDF

Info

Publication number
CN110496231B
CN110496231B CN201810468018.2A CN201810468018A CN110496231B CN 110496231 B CN110496231 B CN 110496231B CN 201810468018 A CN201810468018 A CN 201810468018A CN 110496231 B CN110496231 B CN 110496231B
Authority
CN
China
Prior art keywords
amino acid
amphiphilic polymer
polydopa
block
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810468018.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110496231A (zh
Inventor
孙继红
凌君
岑佳宇
苗岳栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Aosairui Biomedical Technology Co ltd
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201810468018.2A priority Critical patent/CN110496231B/zh
Priority to JP2020564078A priority patent/JP7125725B2/ja
Priority to PCT/CN2019/086586 priority patent/WO2019218960A1/zh
Publication of CN110496231A publication Critical patent/CN110496231A/zh
Application granted granted Critical
Publication of CN110496231B publication Critical patent/CN110496231B/zh
Priority to US17/088,566 priority patent/US20210052749A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Polyamides (AREA)
CN201810468018.2A 2018-05-16 2018-05-16 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用 Active CN110496231B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201810468018.2A CN110496231B (zh) 2018-05-16 2018-05-16 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用
JP2020564078A JP7125725B2 (ja) 2018-05-16 2019-05-13 ポリ３，４－ジヒドロキシ－ｌ－フェニルアラニンキレート第二鉄イオンを含有する両親媒性ポリマーナノミセル及びその使用
PCT/CN2019/086586 WO2019218960A1 (zh) 2018-05-16 2019-05-13 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用
US17/088,566 US20210052749A1 (en) 2018-05-16 2020-11-03 Amphiphilic polymer nano micelle containing poly-3,4-dihydroxyphenylalanine chelated ferric ions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810468018.2A CN110496231B (zh) 2018-05-16 2018-05-16 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用

Publications (2)

Publication Number Publication Date
CN110496231A CN110496231A (zh) 2019-11-26
CN110496231B true CN110496231B (zh) 2020-09-18

Family

ID=68539457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810468018.2A Active CN110496231B (zh) 2018-05-16 2018-05-16 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用

Country Status (4)

Country Link
US (1) US20210052749A1 (https=)
JP (1) JP7125725B2 (https=)
CN (1) CN110496231B (https=)
WO (1) WO2019218960A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306650B (zh) * 2022-01-21 2022-12-06 南方医科大学 一种磁性四氧化三铁纳米粒及其制备方法和应用
CN118987283A (zh) * 2024-10-25 2024-11-22 杭州奥赛瑞生物医药科技有限责任公司 基于聚氨基酸纳米胶束的多模态对比剂及制备方法和应用
CN118987284A (zh) * 2024-10-25 2024-11-22 杭州奥赛瑞生物医药科技有限责任公司 一种聚合物纳米胶束及其在增强ct成像中的应用
CN119033973A (zh) * 2024-10-30 2024-11-29 杭州奥赛瑞生物医药科技有限责任公司 一种透明质酸修饰的铁基聚多巴氨基酸纳米探针及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105524271A (zh) * 2014-10-24 2016-04-27 江苏师范大学 胆酸修饰的聚氨基酸嵌段共聚物的合成及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161020A1 (en) * 2008-09-09 2010-03-10 Koninklijke Philips Electronics N.V. Chelating amphiphilic polymers
KR101721570B1 (ko) * 2011-06-22 2017-03-30 한화케미칼 주식회사 산화철 나노입자 기반 림프절 이미징용 ｍｒｉ 조영제 및 이를 이용하여 림프절을 조영하는 방법
CN104140546B (zh) * 2014-06-27 2017-02-15 江南大学 一种类碳纳米管状可降解聚合物的制备方法
KR101765335B1 (ko) * 2014-09-26 2017-08-22 서울대학교산학협력단 암 세포 조영용 ｍｒｉ 조영제 조성물
CN106916301A (zh) * 2017-04-14 2017-07-04 四川大学 高载铁量聚多巴胺纳米粒子的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105524271A (zh) * 2014-10-24 2016-04-27 江苏师范大学 胆酸修饰的聚氨基酸嵌段共聚物的合成及应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Polycatechol Nanoparticle MRI Contrast Agents;Yiwen Li et al.;《small》;20151217;第12卷(第5期);第668-677页 *
Yiwen Li et al..Polycatechol Nanoparticle MRI Contrast Agents.《small》.2015,第12卷(第5期), *
何旺龙等.多巴胺修饰聚乙二醇的合成及与Fe3+配位研究.《井冈山大学学报(自然科学版)》.2017,第38卷(第1期), *
多巴胺修饰聚乙二醇的合成及与Fe3+配位研究;何旺龙等;《井冈山大学学报(自然科学版)》;20170131;第38卷(第1期);第34-39页 *

Also Published As

Publication number Publication date
US20210052749A1 (en) 2021-02-25
CN110496231A (zh) 2019-11-26
JP2021518479A (ja) 2021-08-02
WO2019218960A1 (zh) 2019-11-21
JP7125725B2 (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
Liu et al. A superparamagnetic polymersome with extremely high T2 relaxivity for MRI and cancer-targeted drug delivery
Kim et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle
AU568740B2 (en) Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents
AU624132B2 (en) Contrast agents for magnetic resonance imaging
Bae et al. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T 1-and T 2-weighted magnetic resonance imaging
Liang et al. One-pot synthesis of Gd 3+-functionalized gold nanoclusters for dual model (fluorescence/magnetic resonance) imaging
CN110496231B (zh) 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用
EP2922577B1 (en) Superparamagnetic iron oxide nanoparticles with ultra-thin polymer layers
Liu et al. Stable gadolinium based nanoscale lyophilized injection for enhanced MR angiography with efficient renal clearance
CN113546087B (zh) 一种纤连蛋白包覆的单宁酸/铁配合物的载药纳米材料及其制备和应用
Luo et al. Hyaluronic acid-mediated multifunctional iron oxide-based MRI nanoprobes for dynamic monitoring of pancreatic cancer
Yon et al. Hybrid polymeric nanostructures stabilized by zirconium and gadolinium ions for use as magnetic resonance imaging contrast agents
CN101862461B (zh) 用于淋巴系统特异成像的含钆大分子造影剂及其制备方法
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
Yan et al. Research progress of magnetic resonance imaging contrast agents
US9682157B2 (en) PH-sensitive imaging agents
Huang et al. Gadolinium-conjugated star-block copolymer polylysine-modified polyethylenimine as high-performance T 1 MR imaging blood pool contrast agents
CN106310297B (zh) 多功能高分子前药纳米递药系统及制备方法和用途
Liu et al. Biocompatible KMnF 3 nanoparticular contrast agent with proper plasma retention time for in vivo magnetic resonance imaging
JP7107532B2 (ja) ナノ粒子、これを含む磁気共鳴イメージング用造影剤及びリガンド化合物
Darvish Mohamadi et al. Gd3+‐DTPA‐Meglumine‐Anionic Linear Globular Dendrimer G1: Novel Nanosized Low Toxic Tumor Molecular MR Imaging Agent
Dong et al. Ultrasmall catechol-PEG-anchored ferrite nanoparticles for highly sensitive magnetic resonance angiography
CN113227040A (zh) 纳米颗粒、包含该纳米颗粒的核磁共振成像造影剂及两性离子配体化合物
HK40129433A (zh) 聚合物包覆的氧化铁纳米棒、制备方法及其应用
HK40050377A (en) Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260202

Address after: 310000 Zhejiang Province Hangzhou City Xiaoshan District Xiaoshan Science and Technology City Qinnong Road No. 2 Jindi.Xindao Lan Valley Building 7 11th Floor 1101 Room

Patentee after: Hangzhou Aosairui Biomedical Technology Co.,Ltd.

Country or region after: China

Address before: 310013 Xihu District, Zhejiang, Yuhang Tong Road, No. 866, No.

Patentee before: ZHEJIANG University

Country or region before: China

TR01 Transfer of patent right